Phathom Pharmaceuticals Inc 2026年季度报告

TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1Financial Statements (unaudited) Condensed Balance SheetsCondensed Statements of Operations and Comprehensive Loss Condensed Statements of Stockholders’ DeficitF-3Condensed Statements of Cash FlowsF-4Notes to Condensed Unaudited Financial StatementsF-5 Item 2Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3Quantitative and Qualitative Disclosures About Market RiskItem 4Controls and Procedures PART II. OTHER INFORMATION Legal Proceedings3434 Item 1ARisk FactorsItem 2Unregistered Sales of Equity Securities and Use of ProceedsItem 3Defaults Upon Senior SecuritiesItem 4Mine Safety DisclosuresItem 5Other InformationItem 6ExhibitsSignatures PHATHOM PHARMACEUTICALS, INC.Condensed Balance Sheets(Unaudited) PHATHOM PHARMACEUTICALS, INC.Condensed Statements of Operations and Comprehensive Loss PHATHOM PHARMACEUTICALS, INC.Condensed Statements of Stockholders’ Deficit(Unaudited) PHATHOM PHARMACEUTICALS, INC.Condensed Statements of Cash Flows(Unaudited) PHATHOM PHARMACEUTICALS, INC.Notes to Condensed Unaudited Financial Statements 1. Organization, Basis of Presentation and Summary of Significant Accounting Policies Organization Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. TheCompany is a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for In May 2022, the U.S. Food and Drug Administration, or FDA, approved the Company's new drug applications, or NDAs forvonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK, and vonoprazan dual therapy, under the brand nameVOQUEZNA DUAL PAK. On October 27, 2023, the FDA approved the prior approval supplements to the Company's NDAs, forVOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Additionally, on November 1, 2023, the FDA approved the Company's NDA forVOQUEZNA tablets. The Company initiated commercial launch for VOQUEZNA in the U.S. for both the Erosive GERD andH. pyloriindications, and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for treatment ofH. pyloriinfection in the fourth quarter of 2023.Additionally, on July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive Liquidity and Capital Resources From inception to March 31, 2026, the Company has devoted substantially all of its efforts to organizing and staffing theCompany, business planning, raising capital, in-licensing its initial and approved product candidate, vonoprazan, meeting withregulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containingvonoprazan, commercially launching its approved products in the U.S., and providing other selling, general and administrativesupport for these operations. The Company has a limited operating history as a commercial company. Although the Company hasgenerated product revenue to date, the amount of future sales and income potential from its business remains uncertain. TheCompany has incurred net losses and negative cashflows from operating activities since its inception and despite the Company's The accompanying unaudited interim condensedfinancial statements have been prepared assuming the Company willcontinue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course ofbusiness, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets oramounts and classification of liabilities in accordance with GAAP. Management is required to perform a two-step analysis over the Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve monthsfrom the date these unaudited interim condensedfinancial statements were issued. There can be no assurance that the Company Basis of Presentation The unaudited interim condensedfinancial statements included herein have been prepared by the Company in accordancewith GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. In the opinion ofmanagement, the accompanying unaudited interim condensedfinancial statements include all adjustments, consisting of normalrecurring adjustments, which are necessary to present fairly the Company’sfinancial position, results of operations, and cashflows.The interim results of operations are not necessarily indicative of the results that may occur for the fullfiscal year. Certain in its Annual Report on Form 10-K for thefiscal year ended December 31, 2025, or the 2025 Form 10-K,filed with the SEC on During the three months ended March 31, 2026, there were no significant changes to the Company’s summary of significantaccounting policies contained in the Company’s 2025 Form 10-K. The Company’s complete listing of significant accoun